In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy.
The in vivo photosensitizing efficacy of mono-L-aspartyl chlorin has been studied by determining the percentage of BALB/c mice cured at varying doses of drug. Using an EMT-6 tumor model, animals received i.p. injections of mono-L-aspartyl chlorin (0.5-100 mg/kg) and then were subsequently exposed to light at 664 nm. Tumor biopsies were taken from selected animals sacrificed at 24 h after treatment and routine histopathological sections made. The other animals remained in the dark for a period of 6 weeks to determine the cure rate. Our results show that mono-L-aspartyl chlorin is an effective tumor localizer that brings about the selective degradation of tumor tissue following light exposure.
D000818:Animals; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D010778:Photochemotherapy; D011166:Porphyrins / Q000627:therapeutic use*
D006415:Hematoporphyrins; D011166:Porphyrins; D017324:Hematoporphyrin Derivative; C053434:Talaporfin